Search Result

Results for "

thromboxane synthase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PGE synthase (1) COX (1) Endogenous Metabolite (1) Prostaglandin Receptor (15)
By Research Areas:	Cancer (2) Cardiovascular Disease (20) Endocrinology (3) Infection (1) Inflammation/Immunology (3) Neurological Disease (1)

Inhibitors & Agonists

Antibodies

Targets Recommended: PGE synthase Thymidylate Synthase ATP Synthase Acetolactate Synthase (ALS) Glucosylceramide Synthase (GCS) NO Synthase Fatty Acid Synthase (FASN) Cyclic GMP-AMP Synthase GSK-3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-106067A

Dazoxiben hydrochloride UK 37248	Others	Inflammation/Immunology
Dazoxiben hydrochloride is a potent and orally active **thromboxane (TX) synthase** inhibitor .

HY-106080A

Furegrelate sodium U-63557A	Others	Cardiovascular Disease
Furegrelate Sodium (U-63557A) is a potent, orally available, and selective **thromboxane synthase** inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC₅₀ of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .

HY-129786

LG 82-4-00	Others	Cardiovascular Disease
LG 82-4-00 is a **thromboxane (TX) synthase inhibitor with an IC₅₀ value of 1.1 μM. LG 82-4-00 can inhibit collagen-induced TXB₂** formation and platelet aggregation in plasma. LG 82-4-00 can be used in studies related to thrombotic diseases .

HY-19189

Terbogrel BIBV 308SE	Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Terbogrel is an orally available thromboxane A2 receptor antagonist and a **thromboxane A2 synthase inhibitor, with both IC₅₀**s of about 10 nM.

HY-106080

Furegrelate U-63557A free acid	Others	Cardiovascular Disease
Furegrelate (U-63557A free acid) is a potent, orally available, and selective **thromboxane synthase** inhibitor. Furegrelate inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC₅₀ of 15 nM. Furegrelate is being developed as an antiplatelet agent .

HY-105114

Imitrodast	Others	Inflammation/Immunology
Imitrodast is an inhibitor of thromboxane synthase. Imitrodast can be used in the research of bronchoconstriction .

HY-106119

Camonagrel	Prostaglandin Receptor	Infection
Camonagrel is a compound that has inhibitory effects on Prostaglandin E2. Camonagrel is a potent thromboxane synthase inhibitor .

HY-116281

ICI D1542	Prostaglandin Receptor	Cardiovascular Disease
ICI D1542 is a selective and potent inhibitor of **thromboxane A2 (TXA2) synthase** and the thromboxane A2 receptor (TP-receptor). ICI D1542 is effective at preventing thrombus formation by redirection of arachidonic acid metabolism .

HY-124150

BM567	Prostaglandin Receptor	Cardiovascular Disease
BM567 is a sulfonylurea compound (compound 1), which exhibits antithrombogenic efficacy as thromboxane A₂ receptor (TXR) antagonists and thromboxane A₂ synthase (TXS) inhibitors, with IC₅₀s of 1.1 and 12 nM, respectively .

HY-118765

Ro 23-3423	Prostaglandin Receptor	Cardiovascular Disease
Ro 23-3423 is a thromboxane synthase inhibitor with an IC₅₀ value of 0.33 μM for human platelet microsomal thromboxane synthase. Ro 23-3423 increases plasma levels of PGF and PGE2 in a dose-dependent manner, accompanied by a decrease in mean systemic arterial pressure and systemic vascular resistance. Ro 23-3423 can be used in the study of general anesthesia .

HY-113445

Thromboxane B3	COX Endogenous Metabolite	Endocrinology
Thromboxane B3 is a prostaglandin analog derived from arachidonic acid (AA) in the cyclooxygenase (COX) metabolic pathway. Thromboxane B3 is generated from arachidonic acid (AA) in platelets and vascular endothelial cells through the catalysis of cyclooxygenase (COX) and thromboxane synthase (TXS). Thromboxane B3 has been reported to be formed by human platelets upon ingestion of eicosapentaenoic acid (C20: 5ω3) .

HY-U00231

KF 13218	Prostaglandin Receptor	Cardiovascular Disease Endocrinology
KF 13218 is a potent, selective and long lasting thromboxane B2 (TXB2) synthase inhibitor with an IC₅₀ value of 5.3±1.3 nM.

HY-B0428A

Ozagrel sodium 1 Publications Verification OKY-046 sodium	Prostaglandin Receptor	Cardiovascular Disease
Ozagrel sodium (OKY-046 sodium) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel sodium is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC₅₀ of 53.12 μM .

HY-B0428B

Ozagrel hydrochloride 1 Publications Verification OKY-046 hydrochloride	Prostaglandin Receptor	Cardiovascular Disease
Ozagrel hydrochloride (OKY-046 hydrochloride) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel hydrochloride is an antiplatelet agent, which selectively inhibits human platelet aggregationwith an IC₅₀ of 53.12 μM .

HY-119890

Isbogrel CV-4151	Prostaglandin Receptor	Cardiovascular Disease Cancer
Isbogrel (CV-4151) is a potent selective inhibitor of thromboxane A2 synthase. Isbogrel has oral activity and inhibits blood TXA2 generation with an ID₅₀ value of 0.04 mg/kg .

HY-B0428

Ozagrel 1 Publications Verification OKY-046	Prostaglandin Receptor	Cardiovascular Disease
Ozagrel (OKY-046)is an anti-asthmatic agent and a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC₅₀ of 53.12 μM .

HY-129199

U-51605	Prostaglandin Receptor	Cardiovascular Disease
U-51605 is a platelet aggregation inhibitor and inhibits thromboxane synthesis. U-51605 is also a prostaglandin I2 synthase inhibitor and can inhibit the retinal vasodilation response induced by NO donors (such as NOR3) .

HY-122178

5-trans U-44069	PGE synthase	Cardiovascular Disease
5-trans U-44069 is the trans isomer of the thromboxane receptor agonist U-44069 (HY-121825). 5-trans U-44069 inhibits prostaglandin E2 synthase activity .

HY-B1735

Picotamide	Prostaglandin Receptor	Cardiovascular Disease
Picotamide is a combined inhibitor of thromboxane A2 (TxA2) synthase and receptor. Picotamide has antiplatelet activity. Picotamide promotes the reduction of microalbuminuria and the inhibition of growth of carotid plaques in diabetes. Picotamide can be used for researching acute or chronic cardiovascular diseases .

HY-A0221

Ridogrel R 68070	Prostaglandin Receptor	Inflammation/Immunology
Ridogrel (R 68070) is an orally active combined thromboxane A2 synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker. Ridogrel is potent antiplatelet agent. Anti-inflammatory activities .

HY-137227

15(R)-PTA2 15(R)-Pinanethromboxane A2	Others	Cardiovascular Disease
15(R)-PTA2 (15(R)-Pinanethromboxane A2) is an antithrombotic agent that inhibits platelet aggregation. 15(R)-PTA2 inhibits stable prostaglandin endoperoxide analog-induced constriction of feline coronary arteries and stabilizes hepatic lysosomes. 15(R)-PTA2 also inhibits thromboxane synthase but has no effect on prostacyclin synthase .

HY-B0428BR

Ozagrel hydrochloride (Standard)	Prostaglandin Receptor	Cardiovascular Disease
Ozagrel (hydrochloride) (Standard) is the analytical standard of Ozagrel (hydrochloride). This product is intended for research and analytical applications. Ozagrel hydrochloride (OKY-046 hydrochloride) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel hydrochloride is an antiplatelet agent, which selectively inhibits human platelet aggregationwith an IC₅₀ of 53.12 μM .

HY-106961

ONO 1301 ONO-AP 500-02	Prostaglandin Receptor	Cardiovascular Disease
ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig .

HY-141469

6,9,12,15,18-Heneicosapentaenoic acid HPA; Heneicosapentaenoic acid methyl ester	Others	Cardiovascular Disease Neurological Disease
6,9,12,15,18-Heneicosapentaenoic acid (HPA; Heneicosapentaenoic acid methyl ester) inhibits the conversion of α-linoleic acid into Arachidonic acid (HY-109590) in hepatoma cells, the activation of prostaglandin H synthase and thromboxane synthesis in isolated platelets. 6,9,12,15,18-Heneicosapentaenoic acid is weak inducer of acyl-CoA oxidase in hepatoma cells .

HY-106961A

(Z)-ONO 1301 (Z)-ONO-AP 500-02	Others	Cardiovascular Disease
(Z)-ONO 1301 is the isomer of ONO 1301 (HY-106961), and can be used as an experimental control. ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig .

HY-117019

LY150310 free base	Others	Cancer
LY150310 is able to inhibit thromboxane synthase, cyclooxygenase, and thrombin activation, biochemical processes that have been proposed in the literature as targets for anti-metastatic agents. The objectives of this study were twofold: (a) to compare the anti-metastatic activity of Eli Lilly compounds with reference anti-metastatic compounds nafazatrom and RA233; and (b) to examine the correlation between inhibition of spontaneous lung metastasis and survival. The anti-metastatic activity of the compounds was evaluated using the Lewis lung squamous cell carcinoma cell model. In this model, 5×10^5 tumor cells were implanted into the gastrocnemius muscle, the primary tumor was resected on day 14, and lung metastatic lesions were counted on day 25. The compounds were administered every 12 hours from day 5 to day 19. Nafazatrom, LY150310, LY189332, and LY135305 were found to inhibit spontaneous lung metastasis in a dose-dependent manner. The ED50 values ??of these compounds were 50, 0.5, 2, and 0.35 mg/kg/day, respectively; the corresponding therapeutic indices (LD50/ED50) were 7, 180, 255, and 511, respectively. To evaluate the effects of nafazatrom, LY150310, LY189332, and LY135305 on animal survival, these compounds were given at the maximum anti-metastatic dose of 200, 60, 20, and 6 mg/kg/day, respectively. Two dosing schedules were used: (a) from day 5 to 19; (b) from day 5 to death. These compounds did not significantly alter median survival times or the number of long-term survivors at any dosing schedule. RA233 did not inhibit lung metastasis or increase median survival time at a schedule in which the maximum tolerated dose of 200 mg/kg/day was given until death on day 5. Postmortem examination of animals given nafazatrom, LY150310, LY189332, and LY1350310 revealed complete suppression of lung lesions, whereas lesions developed in the liver, kidney, spleen, and brain. The results of this study suggest that the effects of a compound on the number of metastatic lesions in target organs may not be predictive of its effects on survival. To successfully translate laboratory data into clinical applications, survival should be considered a predictor of the potential clinical utility of a compound.

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82925

	Thromboxane A Synthase Antibody (YA2670) TBXAS1; CYP5; CYP5A1; thromboxane-A synthase; TXA synthase; TXS; Cytochrome P450 5A1	WB	Human, Mouse
	Thromboxane A Synthase Antibody (YA2670) is a biotin-conjugated non-conjugated IgG antibody, targeting Thromboxane A Synthase, with a predicted molecular weight of 61 kDa (observed band size: 54 kDa). Thromboxane A Synthase Antibody (YA2670) can be used for WB experiment in human, mouse background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.